Microarray profile of the humoral immune response to influenza vaccination in breast cancer patients treated with chemotherapy

M. L. Wumkes*, A. M.T. van der Velden, E. de Bruin, A. Meerveld-Eggink, M. P.G. Koopmans, G. F. Rimmelzwaan, G. T. Rijkers, D. H. Biesma

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Background Patients treated with chemotherapy have an impaired response to influenza virus vaccination compared to healthy controls. Little is known about the broadness of the antibody response in these patients. Methods Breast cancer patients on FEC (5-fluorouracil, epirubicin and cyclophosphamide) chemotherapy regimens were vaccinated with influenza virus vaccine. Sera were obtained before and three weeks after vaccination. In addition to the determination of virus-specific antibody titres by hemagglutination inhibition assay, the broadness of the response was assessed by the use of a protein microarray and baseline titres were compared with an age-matched reference group. Results We included 38 breast cancer patients and found a wide variety in serum antibody response after vaccination. Patients with a history of influenza vaccination had higher pre-vaccination titres, which were comparable to the reference group. Increasing number of cycles of chemotherapy did not have a negative effect on influenza array antibody levels, nor on the HI antibody response. Conclusions Overall there was a broad serum antibody response to the influenza virus vaccine in patients treated with chemotherapy for breast cancer.

Original languageEnglish
Pages (from-to)1299-1305
Number of pages7
Issue number9
Publication statusPublished - 1 Mar 2017

Cite this